ORKA (Oruka Therapeutics) Tax Provision : $ Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Tax Provision?

Oruka Therapeutics's tax provision for the six months ended in Dec. 2024 was $0.00 Mil.

Oruka Therapeutics Tax Provision Historical Data

The historical data trend for Oruka Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Tax Provision Chart

Oruka Therapeutics Annual Data

Trend

Dec24

Tax Provision

Oruka Therapeutics Semi-Annual Data
	Dec24
Tax Provision	-

Oruka Therapeutics Tax Provision Calculation

Tax to be paid.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.